AI-generated analysis. Always verify with the original filing.
Cytokinetics, Incorporated announced that the European Commission has approved MYQORZO® (aficamten), 5 mg, 10 mg, 15 mg and 20 mg tablets for the treatment of symptomatic (New York Heart Association class II-III) obstructive hypertrophic cardiomyopathy in adult patients. MYQORZO is an allosteric and reversible inhibitor of cardiac myosin motor activity.